Figure 5.
Conformational stability evaluation of native bevacizumab, supercritical CO2 treated bevacizumab, and 13, 23, 33, and 4-month in vitro release samples of bevacizumab by (A) circular dichorism (CD), and (B) fluorescence spectroscopy.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.